Generics company Actavis loses lawsuit; NIH looking to fund drug delivery researchers;

> A New Jersey court ruled that Actavis ($ACT) generics violate 7 Depomed patents of its Gralise (gabapentin) tablets for the management of postherpetic neuralgia, which are based on its proprietary Acuform drug delivery technology. Release | Story

> Drug delivery specialist EastGate Acquisitions said that it is trying to acquire the licensing rights to develop and manufacture an intraoral insulin formulation. Release

> The FDA issued a Class I recall of Enhancement Medical's Expression intranasal splint, saying it is dangerous when injected subcutaneously, especially when used off-label as a dermal filler. Story

> The U.S. National Institutes of Health is inviting scientists to apply for funding of research into platform delivery technologies for nucleic acid therapeutics. Announcement

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.